MedPath

Vigil Neuroscience

Vigil Neuroscience logo
🇺🇸United States
Ownership
Public
Established
2020-01-01
Employees
69
Market Cap
$137.1M
Website
http://www.vigilneuro.com
Introduction

Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.

Clinical Trials

4

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease

Phase 1
Completed
Conditions
Healthy
Alzheimer Disease
Interventions
Drug: Placebo
First Posted Date
2024-04-02
Last Posted Date
2025-02-07
Lead Sponsor
Vigil Neuroscience, Inc.
Target Recruit Count
115
Registration Number
NCT06343636
Locations
🇺🇸

K2 Medical Research, Maitland, Florida, United States

🇦🇺

Nucleus Network, Melbourne, Australia

🇺🇸

Clinical Pharmacology of Miami, Miami, Florida, United States

A Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia

Phase 2
Terminated
Conditions
ALSP
Interventions
First Posted Date
2023-01-10
Last Posted Date
2025-06-11
Lead Sponsor
Vigil Neuroscience, Inc.
Target Recruit Count
20
Registration Number
NCT05677659
Locations
🇺🇸

Investigative Site 3, San Francisco, California, United States

🇺🇸

Investigative Site 2, Englewood, Colorado, United States

🇺🇸

Investigative Site 1, Jacksonville, Florida, United States

and more 7 locations

Natural History Study in Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia

Terminated
Conditions
ALSP
First Posted Date
2021-08-25
Last Posted Date
2025-06-11
Lead Sponsor
Vigil Neuroscience, Inc.
Target Recruit Count
56
Registration Number
NCT05020743
Locations
🇺🇸

Investigative Site 4, San Francisco, California, United States

🇺🇸

Investigative Site 5, Englewood, Colorado, United States

🇺🇸

Investigative Site 1, Boca Raton, Florida, United States

and more 9 locations

News

No news found
© Copyright 2025. All Rights Reserved by MedPath